Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAC as add-on to SSRIs in MDD
NCT02269540Phase 1Completed
- Sponsor
- Center for Addiction and Mental Health
- Start
- Oct 2014
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of acetylcysteine in major depressive disorder (MDD), sponsored by Center for Addiction and Mental Health. Started Oct 2014; status: completed.
02
Drugs
acetylcysteine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02269540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02269540.